Close Menu

NEW YORK (GenomeWeb) – Bio-Rad reported after the close of the market Tuesday that its first quarter revenues increased 10 percent year over year driven by growth in both its Life Science and Clinical Diagnostics businesses.

For the three months ended March 31, Bio-Rad tallied net sales of $551.5 million compared to $500.1 million in Q1 2017, beating analysts' consensus estimate of $527.2 million. On a currency-neutral basis, Q1 sales increased 4.5 percent year over year, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.